CinCor Pharma (CINC) IPO Opens 31% Higher

Today's IPO for CinCor Pharma, Inc. (Nasdaq: CINC) opened for trading at $21 after pricing 12,100,000 shares of common stock at a price to the public of $16.00 per share.

Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager for the offering.

CinCor, is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.

You May Also Be Interested In

• Kardigan raises $460M in IPO on Nasdaq
• Neutron Holdings files for IPO on Nasdaq under ticker LIME
• Doncasters Group guiding IPO pricing at top of range - Bloomberg